Skip to main content
Premium Trial:

Request an Annual Quote

Decode s Q4 Revenues Decline Slightly as Loss Nearly Doubles

NEW YORK, March 4 (GenomeWeb News) - Decode Genetics yesterday reported slightly decreased revenues for the fourth quarter of 2004, while losses almost doubled.

 

Revenues totaled $11.2 million for the quarter, down from $11.7 million during the same period a year ago.

 

R&D expenses increased to $8.7 million from $5.8 million during the fourth quarter of 2003. This increase was mainly due to costs associated with clinical trials for two compounds, according to Decode.

 

Decode's net loss for the further quarter was $19.4 million, or $.36 per share, up from $10.6 million, or $.20 per share, during the same period in 2003. This steep increase resulted from costs of clinical trials, debt service, and the impact of foreign exchange fluctuations, according to the company.

 

As of Dec. 31, 2004, Decode had $198.3 million in cash and investments, including restricted cash, cash equivalents, marketable securities, and other investments.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.